Allergan, Celgene among analysts' favorite pharma stocks heading into 2018
Allergan plc, Celgene Corp. and Biogen Inc. had the most favorable consensus recommendations from analysts who cover the biopharmaceutical industry. GlaxoSmithKline plc and Sanofi were the least favorable among the 20 largest biopharmaceutical companies by market value.
Regeneron seeks to carve out a piece of the crowded cancer combo market
Regeneron Pharmaceuticals Inc. as a late entrant in the immuno-oncology race is seeking to make its mark with novel combinations of PD-1 inhibitors, chemotherapy, radiation and various cytokine-targeting drugs. The company recently reported positive phase 2 trial results for Regeneron's cancer treatment cemiplimab for skin cancer.
Capitol Checkup: Collins relevant again; CDC word fight; FDA flattery strategy
Sen. Susan Collins' support for the Republican tax reform package may be relevant again as at least one Republican senator may not be present to vote on the bill. This may give Collins leverage to get two healthcare bills through the House and the Senate.
US FDA lifts clinical hold on Sanofi, Alnylam's hemophilia trial
Sanofi and Alnylam Pharmaceuticals Inc. can now continue their research on hemophilia treatment fitusiran after the U.S. Food and Drug Administration lifted the hold on clinical studies that was imposed due to safety concerns following a patient death. The studies to be undertaken include the phase 2 open-label extension study, which reported the patient death, and the Atlas phase 3 program.
Tax bill's individual mandate repeal could weaken health market: news analysis
Industry experts told S&P Global Market Intelligence that a repeal of the Affordable Care Act's individual mandate or its enforcement mechanism would undermine the law's purpose of insuring more Americans and that the impact on the health insurance industry could be severe.
CAR-T therapies promising but cost questions remain, US price group says
The Institute for Clinical and Economic Review concluded that the emerging chimeric antigen receptor T cell therapies show promise but cost remains a concern, with Novartis AG's Kymriah at a cost of $475,000 and Gilead Sciences Inc.'s Yescarta at $373,000. Along with the cost, manufacturing capacity for the therapy's complex engineering process is also something that requires attention.